Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this first in human study is to evaluate the feasibility, safety, and efficacy
of administering TBio-4101 (tumor infiltrating lymphocytes [TIL]) after receiving a
lymphodepleting chemotherapy regimen and before receiving interleukin-2 (IL-2) in
participants with unresectable or metastatic melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute